---
title: "Shanghai Haohai Biological Technology Co.,Ltd (688366.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688366.SH.md"
symbol: "688366.SH"
name: "Shanghai Haohai Biological Technology Co.,Ltd"
industry: "Biotechnology"
datetime: "2026-05-20T11:26:41.508Z"
locales:
  - [en](https://longbridge.com/en/quote/688366.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688366.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688366.SH.md)
---

# Shanghai Haohai Biological Technology Co.,Ltd (688366.SH)

## Company Overview

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and other ophthalmic medical products; hyaluronic acid and chitosan; and electronic instruments, such as semiconductors, optoelectronics, lasers, radio frequency, and ultrasonic instruments. It also engages in the research and development of biological engineering and pharmaceutical products and related technology transfer activities, consulting, and other services; research, development, production, and sales of radio frequency instruments; cell technology and biochemical product technology research and development; computer, communication, and other electronic equipment manufacturing; instrument manufacturing; manufacture and sale of biological reagents, biological agents, and biological materials; medical-grade sodium hyaluronate bio-based skincare products; intraocular lens and related products; intraocular lens injectors and materials, equipment, chemical products, and accessories for contact lenses and artificial lenses; sale of ophthalmology products; and provision of other machines and accessories.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.3healthcare.com](https://www.3healthcare.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.49)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 40 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -9.54% |  |
| Net Profit YoY | -43.31% |  |
| P/B Ratio | 1.53 |  |
| Dividend Ratio | 2.74% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8356243968.38 |  |
| Revenue | 2403466487.52 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.22% | C |
| Profit Margin | 9.76% | B |
| Gross Margin | 66.32% | A |
| Revenue YoY | -9.54% | D |
| Net Profit YoY | -43.31% | D |
| Total Assets YoY | -6.47% | D |
| Net Assets YoY | -5.91% | D |
| Cash Flow Margin | 180.86% | B |
| OCF YoY | -9.54% | D |
| Turnover | 0.35 | D |
| Gearing Ratio | 15.99% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Haohai Biological Technology Co.,Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-9.54%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-43.31%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.53",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.74%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8356243968.38",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2403466487.52",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.22%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "9.76%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "66.32%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-9.54%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-43.31%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-6.47%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-5.91%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "180.86%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-9.54%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.35",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "15.99%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 35.61 | 14/81 | 32.30 | 29.92 | 27.85 |
| PB | 1.53 | 13/81 | 2.17 | 2.08 | 1.73 |
| PS (TTM) | 3.44 | 5/81 | 4.67 | 4.47 | 3.85 |
| Dividend Yield | 2.74% | 8/81 | 2.36% | 2.10% | 1.87% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-31T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 35.35 |
| Highest Target | 45.00 |
| Lowest Target | 45.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688366.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688366.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688366.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/688366.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**